Stabilised solid compositions of factor VII polypeptides
The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.
1. A composition comprising a human Factor VIIa polypeptide and a combination of sucrose and a polyol, said composition having a moisture content of not more than about 3%.
2. The composition according to claim 1 , wherein the composition further comprises an antioxidant.
3. The composition according to claim 2 , wherein the antioxidant is selected from the group consisting of homocysteine, cysteine, cystathionine, methionine, glutathione, and peptides containing any one of homocysteine, cysteine, cystathionine, methionine, and glutathione.
4. The composition according to claim 1 , wherein the polyol is selected from the group consisting of mannitol, sorbitol and xylitol.
5. The composition according to claim 1 , wherein the composition is stable such that not more than about 5% w/w of the initial content of the human Factor VIIa polypeptide is converted to aggregates upon storage of said composition at 30° C. for 8 months.
6. The composition according to claim 1 , wherein the composition is stable such that not more than about 6% w/w of the initial content of the human Factor VIIa polypeptide is converted to oxidized forms upon storage of said composition at 30° C. for 8 months.
7. The composition according to claim 1 , wherein said polyol is in an amount ranging from about 5% w/w to 90% w/w.
8. The composition according to claim 1 , wherein said polyol is in a weight ratio relative to said saccharide ranging from about 100:1 to 1:50.
9. The composition according to claim 1 , further comprising an agent suitable for keeping the pH of said composition in the range of 3 to 9 when dissolved in aqueous solvent.
10. The composition according to claim 9 , wherein said agent is selected from the group consisting of citrate, acetate, histidine, malate, phosphate, tartaric acid, succinic acid, MES, HEPES, PIPES, imidazol, TRIS, lactate, glutamate and glycylglycine.
11. The composition according to claim 1 , further comprising a tonicity modifier.
12. The composition according to claim 11 , wherein the tonicity modifier is selected from the group consisting of sodium acetate, sodium lactate, sodium chloride, potassium chloride and calcium chloride.
13. The composition according to claim 1 , further comprising a surfactant.
14. The composition according to claim 13 , wherein the surfactant is selected from the group consisting of polysorbates, polyoxyethylene alkyl ethers, poloxamers, ethylene/polypropylene block polymers, and polyethyleneglycols (PEGs).
15. The composition according to claim 1 , further comprising one or more other pharmaceutical excipients acting as a bulking agent.
16. The composition according to claim 1 , wherein the polyol is mannitol.
17. The composition according to claim 1 , wherein the human Factor VIIa polypeptide is recombinant human Factor VIIa.
18. The composition according claim 1 , wherein the human Factor VIIa polypeptide is present in a concentration of from about 0.6 mg/ml to about 10.0 mg/ml.
19. The composition according to claim 1 , wherein said moisture content is not more than about 2.5% w/w.
20. The composition according to claim 1 , wherein the composition is a lyophilised cake.
21. The composition according to claim 1 , wherein the composition comprises: human Factor VIIa polypeptide, mannitol, sucrose, and a surfactant selected from the group consisting of a polysorbate and a poloxamer.
22. The composition according to claim 21 , further comprising methionine.
23. The composition according to claim 21 , further comprising L-histidine.
24. The composition according to claim 21 , further comprising one or more components selected from the group consisting of: CaCl 2 , NaCl, and Glycylglycine.